Loading grant details…
Active
NON-SBIR/STTR RPGS
NIH (US)
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells
$6.91M
USD
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Brigham and Women'S Hospital |
| Country | United States |
| Start Date | Jun 21, 2024 |
| End Date | May 31, 2029 |
| Duration | 1,805 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10978903 |
Grant Description
PROJECT SUMMARY Immunotherapy holds the promise of a cure for cancer. However, only a subset (
All Grantees
Brigham and Women'S Hospital
Advertisement
Advertisement
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Start Year
2024
End Year
2029
Grantees
1
Related Grants
AIDS Clinical Trials Group for Research on Therapeutics for...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$762.2K USD
Leadership and Operations Center (LOC), AIDS Clinical Trials...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$715K USD
Development of outpatient antiviral cocktails against SARS-C...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$690.6K USD
Advertisement
